The four proteins CDK8, Cyclin C, Med12, and Med13 can associate with Mediator and are presumed to form a stable "CDK8 subcomplex" in cells. Here we describe the isolation and enzymatic activity of 10 the 600 kDa CDK8 subcomplex purified directly from human cells and also via recombinant expression in insect cells. Biochemical analysis of the recombinant CDK8 subcomplex identifies predicted (TFIIH, pol II CTD) and novel (histone H3, Med13, CDK8 itself) substrates for the CDK8 kinase. Notably, these novel substrates appear to be metazoan-specific. Such diverse targets imply strict regulation of CDK8 kinase activity. Along these lines, we observe that Mediator itself enables 15 CDK8 kinase activity on chromatin, and we identify Med12-but not Med13-as essential for activating the CDK8 kinase. Moreover, mass spectrometry analysis of the endogenous CDK8 subcomplex reveals several associated factors, including GCN1L1 and the TRiC chaperonin, that may help control its biological function. In support of this, electron microscopy analysis suggests TRiC sequesters the CDK8 subcomplex and kinase assays reveal the endogenous CDK8 subcomplex-unlike 20 the recombinant submodule-is unable to phosphorylate the pol II CTD.
The Mediator complex is a general target of DNA-binding transcription factors and is required for expression of virtually all protein-coding genes (35) . Four subunits-CDK8, Cyclin C, Med12, and Med13-are known to reversibly associate with Mediator and modulate its biochemical function. In humans, CDK8, Cyclin C, 25
Med12, and Med13 are believed to associate as a subcomplex based in part upon biochemical and genetic experiments in yeast and lower metazoans. In fact, a stable "CDK8 subcomplex" containing CDK8, Cyclin C, Med12, and Med13 has been isolated from yeast cells expressing TAP-tagged Cyclin C (5) . Genetic experiments in yeast, C. elegans, and Drosophila indicate that CDK8, Cyclin C, Med12, and Med13 are each required for organism (but not cell) viability and function primarily as a unit (6, 20, 33, 53) . That is, similar 30 phenotypes result from mutation of any single subunit within the CDK8 subcomplex (7) . Furthermore, the expression of CDK8, Cyclin C, Med12, and Med13 is regulated differently with respect to other consensus Mediator subunits, at least in yeast (20) . Genetic studies have also revealed that components of the CDK8 subcomplex play critical roles in development (60) . For example, ablation of the CDK8 kinase in mice results in lethality at the pre-implantation stage (57) ; deletion of Med12 causes severe defects in brain and 35 neuronal development in C. elegans and zebrafish (21, 47, 56, 61), whereas loss of either Med12 or Med13 causes identical defects in Drosophila eye and wing development (23, 52) . Significantly, a number of disease-causing mutations in CDK8 subcomplex components are beginning to be uncovered in humans. For instance, a single point mutation in Med12 (R961W) has been linked to a rare syndrome affecting brain development and mutations within a different region in Med12-the Q-rich domain in its C-terminus-can 40 cause mental retardation in males (46, 48) . Furthermore, congenital heart and neuronal defects can result from mutations within an isoform of Med13 (39) , and CDK8 has been directly implicated in oncogenesis (12, 38) .
Clearly, the subunits within the CDK8 subcomplex are important for proper control of developmental 45 programs, yet the biochemical mechanisms by which they regulate these processes are not fully defined. For one, it is unclear whether the CDK8 subcomplex functions only in the context of Mediator or whether it may operate in part as a separate, independent entity. Furthermore, no biochemical function has been attributed to Med12 or Med13, which together comprise a major portion (500 kDa) of the 600 kDa CDK8 subcomplex. Indeed, nearly all known regulatory functions of the CDK8 subcomplex have been attributed to its kinase 50 activity (20, 40) . For example, phosphorylation of different activators by yeast CDK8 (also called srb10) can
Purification of the endogenous CDK8 subcomplex
See Figure 5 for overview of purification protocol. A typical preparation started with HeLa nuclear extract 90 from 500L of cells; this was loaded on a Whatman P11 phosphocellulose column at 0.1M KCl and eluted with 0.3M KCl, 1mM MgCl 2 HEG, dialyzed to 0.15M KCl, and passed over a HiTrap Q column (GE Healthcare). Flow through fractions were precipitated by addition of 50% w/v ammonium sulfate and further concentrated with Amicon spin filters (Millipore). Residual Mediator was depleted by GST-SREBP affinity chromatography. Superose 6 fractionation isolated 400-800kDa complexes. After pre-clearing with 95 protein A/G resin (GE Healthcare), concentrated Superose 6 fractions were incubated with anti-CDK8 antibody bound A/G resin, washed with 50cv 0.5M KCl HEGN, 10cv 0.15M KCl HEGN, and eluted with 50mM Tris pH8.0, 0.75M ammonium sulfate, 40% ethylene glycol, 0.1mM EDTA. Elutates were desalted into 0.15M KCl HEGN with a Quick Spin TE column (Roche) pre-blocked with BSA, loaded onto a glycerol gradient containing 100µl 30%, 850µl 20%, and 1150µl 15% glycerol in 0.15M KCl HEGN and spun as 100 stated above. Endogenous CDK8 subcomplex was retained in the 30% glycerol fraction.
CDK8 subcomplex stoichiometry experiments
A modified CTD truncated GST tagged Med12 (GST-Med12 aa1-1227) was incorporated into the recombinant CDK8 kinase dead complex using the techniques outlined above. Having tags on two of the 105 subunits (Glu-CDK8 and GST-Med12 aa1-1227) allowed for the multi-step affinity purifications summarized in Figure 2 . Purifications included combinations of the following procedures: 1) Glu purification as described above; 2) GSH-resin purification; 3) Glycerol gradient sedimentation (as outlined in above) using 20-80% glycerol; 4) Anti-Med13 immunoprecipitation followed by elution with 2% sarkosyl. As sarkosyl disrupted protein-protein interactions, the anti-Med13 purification technique could be 110 used only as a final step. For each affinity purification step (1-4, above), bound material was washed extensively with 0.3-0.5M KCl HEGN prior to elution from the resin. Following tandem purifications, proteins were separated by SDS-PAGE and stained with SYPRO Ruby or Coomassie protein stains and quantitated using densitometry. 115
Purification of CDK8-Mediator Nuclear extract from 100L of HeLa cells was passed over a phosphocellulose column as described above. Following the 0.3M KCl wash Mediator was eluted 0.5M KCl HEG and loaded onto a HiTrap Q column (GE Healthcare). The flow through from the Q column was incubated with GST-SREBP or GST-VP16 bound GSH resin, washed with 250cv 0.5M HEGN, 50cv 0.15M KCl HEGN eluted with 30mM GSH and 120 run on a linear 15-40% glycerol gradient.
Mass spectrometry
Recombinant CDK8 subcomplex or TCA precipitated endogenous CDK8 subcomplex samples were prepared for analysis by mass spectrometry as described previously (25). Briefly, the samples were 125 separated by SDS PAGE, SYPRO stained, reduced with DTT, alkylated with iodoacetamide, and digested overnight with trypsin (Promega). Recombinant protein identification was done using an Agilent LC/MSD Trap XCT fed by an Agilent 1100 series HPLC, while endogenous samples were run through a Waters nanoACUITY UPLC coupled to a Thermo Finnigan LTQ. The resulting MS/MS data was searched using the MASCOT search engine against the human IPI database. 130
Kinase assays
Reactions were carried out with 5-50ng purified CDK8 subcomplex and 125-500ng purified substrate in kinase buffer (25mM Tris pH 8.0, 100mM KCl, 10-100µM ATP, 10mM MgCl 2 , and 2mM DTT) with the addition of 2.5µCi γ-32 P ATP at 30º C for 60 minutes. Reactions were separated by SDS PAGE, silver 135 stained, dried, exposed on a Storage Phosphor Screen (GE Healthcare) and imaged with a Typhoon 9400 scanner (GE Healthcare). For kinase assays involving DNA-PK, 500ng linear DNA was added to activate DNA-PK and 2µM wortmannin was used to inhibit DNA-PK function. Purified DNA-PK was obtained from Promega (V5811). 140
Phosphorylation specific EMSA Recombinant wild type or kinase dead 4-protein CDK8 subcomplexes were incubated at 30ºC for 60 minutes in kinase buffer (50 mM Tris pH 7.9, 100mM NaCl, 10 mM MgCl 2 , and 1 mM DTT) or in phosphatase buffer (supplemented with calf intestinal phosphatase) at 37º C for 60 minutes. Proteins were then separated by 5% SDS PAGE and visualized by silver stain. 145 Antibodies Santa Cruz: Med12 (sc-5374), CDK8 (sc-1521), Cyclin C (sc-1061), H3 (sc-8654), GST tag (sc-138), TCP-1 β (sc-1378), DNA-PK (sc-1552), Nucleolin (sc-8031). Upstate: H3 phospho-S10 (06-570), H3 phospho-S28 (07-145), H3 phospho-T3 (07-424). Bethyl, Inc: Med13 (A301-278A), Med23 (A300-425A). Abcam: Glu 150 tag (ab1267), His tag (ab9108). Covance: pol II (8WG16), pol II S2P (MMS-129R), pol II S5P (MMS-134R). Lab stock: Med14.
Purification of core histones
Expression and reconstitution of recombinant core histones was completed as described (34) . Purification of 155
Drosophila core histones was completed as described (27).
Chromatin assembly
Drosophila core histones were assembled with digested 5S G5E4 DNA into chromatin using the salt dialysis method as described (22) . Assembled chromatin was visualized by ethidium bromide staining of phenol 160 chloroform extracted micrococcal nuclease digested samples.
Cell Culture HCT116 and HEK293 cells were maintained in McCoy's 5A and DMEM (Gibco-Invitrogen), respectively, supplemented with 10% fetal bovine serum and an antibiotic/antimycotic mix. 165
CDK8 and Med12 knockdowns
Short-hairpin RNAs (shRNAs) targeting either CDK8 or MED12 were generated and expressed using the third generation lentiviral delivery system previously described with minor modifications (10, 41) . Briefly, complementary oligos, encoding shRNAs were cloned into the lentiviral vector, pLL3.7neo (a derivative of 170 the original pLL3.7 vector with the coding region of GFP replaced with coding region of neomycin phosphotransferase). The shRNA/pLL3.7neo vectors were co-transfected into HEK293FT cells along with the packaging vectors pMDLg/pRRE, pRSV-REV, and pMD.G. 48 hours later viral supernatants were harvested and used to transduce HCT116 cells. HCT116 clones that were neomycin resistant were grown and screened by immunoblot for knockdown of the appropriate target. Cells were lysed in RIPA buffer 175 supplemented with a cocktail of protease and phosphatase inhibitors.
Electron microscopy
Endogenous CDK8 subcomplex samples were negatively stained with uranyl acetate, imaged at 29,000x magnification on a Tecnai F20 FEG equipped with a Gatan 4k x 4k CCD camera, and segregated into 2D 180 classes as described (36) .
S6 fractionation of HeLa Nuclear Extracts
HeLa nuclear extracts were first concentrated by ammonium sulfate precipitation (50% w/v). Concentrated nuclear extract was passed through a Superose 6 10/300 GL column (GE Healthcare). Immunoblots of 185 fractions collected were quantitated using densitometry. Fractions larger than 1.4 MDa were considered to contain CDK8-Mediator, whereas fractions ranging from 1.4MDa to 400kDa were considered as eK8, and fractions with protein complexes smaller than 400kDa were considered to consist of partial subcomplexes.
Quantitative western analysis of Superose 6-fractionated HeLa nuclear extracts resulted in estimates of 190 approximately 30% of CDK8 subcomplex components present in the fractions between 1.4MDa and 400kDa-fractions consistent with the size of the endogenous CDK8 subcomplex. In agreement with this, when fractionated over a phosphocellulose column, about 30% of the total amounts of the CDK8 subcomplex components probed were retained in the P0.3M fraction (see Fig. 6A ). As the P0.3M fraction is greatly enriched for the endogenous CDK8 subcomplex, we view this as further evidence that as much as 195 30% of CDK8 subcomplexes may exist independently of Mediator in human cells. Proportionally more CDK8 (over 50%) was found in the 400kDa -1.4MDa fractions, implying that other large complexes containing CDK8 may exist.
RESULTS AND DISCUSSION 200
Recombinant CDK8 subcomplexes. To generate the recombinant CDK8 subcomplex, Sf9 cells were coinfected with high-titer viruses for CDK8, Cyclin C, Med12, and Med13. The CDK8 subcomplex was purified from whole cell extracts by immunoprecipitation with an anti-Glu resin, which targeted the Glu-tagged CDK8 subunit within the subcomplex. Fractionation of the extracts over ion-exchange and gel 205 filtration columns prior to immunoprecipitation did not measurably improve the purity of the subcomplex (data not shown). A similar strategy was used to purify the kinase-dead CDK8 subcomplex, which contained a D173A point mutation in CDK8 that inactivates its kinase function (1). Silver-stained gels of the active (r 4wt) and kinase-dead (r 4kd) CDK8 subcomplexes are shown in Figure 1A . Importantly, each subunit comigrated on a glycerol gradient, confirming their association in a large complex (data not shown).
210
Immunoblots and ESMS analysis confirmed the identity of each subunit as Med13, Med12, CDK8, and Cyclin C (Fig. 1 B,C) . Furthermore, a 1:1:1:1 stoichiometry was established for the CDK8 subcomplex based upon densitometry measurements (see below). Thus, it appeared that human CDK8, Cyclin C, Med12, and Med13 could assemble into a stable complex from recombinantly-expressed subunits. 215
Comparison of silver-stained gels of the wild-type (4wt) and kinase-dead (4kd) CDK8 subcomplexes revealed a shift in Med13 and/or Med12 mobility, suggesting that these subunits may be phosphorylated by CDK8. To test this, we treated the recombinant wild-type (r 4wt) or kinase-dead (r 4kd) complexes with either ATP or phosphatase prior to gel electrophoresis. As shown in Figure 1D , these experiments indicated the mobility shifts were due to differential phosphorylation; western blots (not shown) and ESMS data 220 confirmed that phosphorylation was occurring on Med13 (see below).
To explore a potential biochemical function for Med12 and Med13, we expressed and purified the CDK8/Cyclin C pair alone and also together with either Med12 or Med13. Each 3-subunit complex (CDK8/Cyclin C/Med12, or CDK8/Cyclin C/Med13) as well as the CDK8/Cyclin C binary complex was 225 stable and could be purified using standard techniques, indicating that Med12 and Med13 each independently interact with the CDK8/Cyclin C pair (Fig. 1A, B ). Subunits within these partial subcomplexes also comigrated on a glycerol gradient, confirming their assembly in a complex (data not shown). Together, these stable, recombinant subcomplexes offered a means to systematically examine the kinase activity of the CDK8 subcomplex. 230
A 1:1:1:1 stoichiometry for CDK8:Cyclin C:Med12:Med13 within the CDK8 subcomplex Assessing the stoichiometry of the CDK8 submodule was complicated by several factors. First, Med13 is phosphorylated, which impacts its migration on a gel and causes it to overlap with the Med12 protein band. Specifically, Med13 in its unphosphorylated state migrates slightly below Med12, whereas in intermediate 235 stages it overlaps with Med12; highly phosphorylated forms of Med13 will migrate larger than Med12 (See Fig. 1D ). Because of its multiple phosphorylated states, Med13 is represented by multiple bands which hinders an accurate quantitation. Thus Med12, which shows no evidence of phosphorylation, represents a more reliable subunit for quantitation. However, because of overlapping Med12/Med13 bands, accurate quantitation of Med12 apart from Med13 was not possible. To remedy this problem, we expressed a CTD-240 truncated version of Med12 (residues 1-1227). This Med12 truncation does not impact its association with the subcomplex and has no apparent differences from full length Med12 on impacting the CDK8 submodule kinase activity (data not shown). With respect to quantitation, this truncated form of Med12 enables a clear separation between Med12 and Med13 on a gel to accurately quantify Med12. 245
With respect to CDK8/Cyclin C, we focused on Cyclin C, because, like Med13, CDK8 presents multiple obstacles to accurate quantitation. First, CDK8, like Med13, is phosphorylated and therefore migrates as several bands. Second, the CDK8 band overlaps slightly with a non-specific band that may represent the heavy chain from the antibody purification (Fig. 2) . Fortunately, such issues do not accompany Cyclin C. Thus, to ensure the most accurate results, we focused on Med12 and Cyclin C for the assessment of 250 stoichiometry within the CDK8 submodule. The results, which indicate a 1:1 stoichiometry for Cyclin C and Med12, are summarized in Figure 2 . Densitometry readings from Coomassie-stained gels were also consistent with a 1:1 stoichiometry between Cyclin C and Med12. Despite the potential uncertainty in quantitation of CDK8 in these samples (noted above), the molar ratio of Cyclin C to CDK8 ranged from 1:0.73 to 1:1.31 in our experiments, also suggesting a 1:1 overall stoichiometry. This could also be 255 anticipated based upon predicted CDK8/Cyclin C pairing within the complex.
Despite the problems associated with assessing the molar ratio Med13 with densitometry (see above), it is worth noting that our measurements suggested a 0.5:1 ratio of Med13 relative to Cyclin C. We are quite confident the true molar ratio is 1:1 because of the uncertainty due to its multiply-phosphorylated states and 260 also for additional reasons outlined below. First, in testing alternate purification protocols for the CDK8 subcomplex, we noted that Med13 could be selectively dissociated with 500 mM imidazole, suggesting that Med13 may be slightly labile within the subcomplex. Second, using titration gel densitometry techniques (plotting band intensity vs. sample load), we noted that Med13 increased at the same ratio (i.e. the same slope) as Cyclin C, suggesting a 1:1 ratio. Third, the molecular mass of a 1:1:1:1 subcomplex (600 kDa) is 265 consistent with our EM data of the recombinant CDK8 subcomplex (M.K. and D.T., unpublished results), whereas a 950 kDa subcomplex (required for a 2:2:2:1 ratio) is not. Taken together, these data suggest Med13 is present in a 1:1 molar ratio with Cyclin C and the stoichiometry of each subunit within the CDK8 subcomplex is 1:1. 270
Identification of novel substrates for the CDK8 kinase. Although few substrates have been identified for human CDK8, this kinase clearly plays important roles in gene regulation (1) and has been linked to oncogenic transformation in colon cancer (12, 38) . Known substrates of CDK8 include TFIIH and the CTD of the large subunit of pol II (1, 31). As expected, the recombinant human subcomplex phosphorylated TFIIH (data not shown) and the pol II CTD, whereas the subcomplex containing a point mutation in CDK8 275 did not (Fig. 3A, lanes 4 and 5) . Phosphorylated bands corresponding in size to CDK8 and Med13/Med12 were also evident with the active CDK8 subcomplex, but not in assays with the kinase-dead mutant (Fig. 3A , compare lanes 4 and 5). Subsequent ESMS analysis of each phosphorylated band confirmed their identities as CDK8 and Med13 (data not shown). Because Med13 and CDK8 were phosphorylated in the active subcomplex, but not the kinase-dead counterpart, we conclude that CDK8, and not a potential contaminating 280 kinase activity, was phosphorylating these substrates. Phosphorylation of CDK8 and Med13 was also observed in the context of the entire CDK8-Mediator complex (Fig. 3A , lane 6), indicating that subunit specificity is not altered upon subcomplex association with core Mediator. CDK8-Mediator was also observed to phosphorylate the pol II CTD, as expected (data not shown). The absence of additional kinase substrates within Mediator itself suggests that the CDK8 subcomplex occupies a distinct, separable domain 285 within CDK8-Mediator, consistent with past structural studies (50) .
During the course of this work, our lab isolated a derivative CDK8-Mediator complex that efficiently phosphorylated histone H3 in vitro (36) . This result suggested that CDK8 is a histone H3 kinase, at least when associated with Mediator. To test whether the recombinant CDK8 subcomplex alone would display 290 similar H3 kinase activity, we performed kinase assays against purified core histone octamers. The recombinant wild-type CDK8 subcomplex-but not the kinase-dead mutant-preferentially phosphorylated histone H3 within core histone octamers (compare Fig. 3B lanes 5 and 6) . Similar results were obtained with recombinant core histones (data not shown). As an additional control, we purified human TFIIH (Fig.  3C ) to test in the histone kinase assays. TFIIH is generally required to initiate transcription and contains a 295 kinase, CDK7, that is critical for its biochemical function. Both CDK8 and CDK7 are capable of modifying the pol II CTD in vitro (Fig. 3D) ; however, TFIIH was unable to phosphorylate histone octamers in this assay (Fig. 3B, lane 7) , indicating a significant difference in CDK7 vs. CDK8 substrate specificity. Given the emerging role of H3 phosphorylation in active gene expression (see below), this observation identifies a means by which CDK8 may positively regulate gene expression in human cells. 300
To identify the H3 residue(s) modified by the CDK8 subcomplex, we focused on the N-terminal tail of histone H3, which is a common site for post-translational modifications. A series of kinase assays with purified, recombinant H3 were performed; antibodies against different phosphorylated forms of H3 were then used to probe for potential site(s) of CDK8 modification. As shown in Figure 3E , these experiments 305 revealed that H3S10, but not H3T3 or H3S28, is the major site for phosphorylation by the CDK8 subcomplex. Notably, whereas phosphorylation of H3T3 or H3S28 does not correlate with transcription, H3S10 phosphorylation is strongly tied to transcriptional activation (44) . For example, H3S10 phosphorylation helps maintain a transcriptionally active state by inhibiting methylation of the adjacent H3K9 site, thereby preventing assembly of repressive HP1 complexes on chromatin (13, 19) . Moreover, 310 H3S10 phosphorylation strongly correlates with activation of genes regulated by such diverse activators as NF-κB, RARβ2, and myc in human cells (3, 28, 59, 64); furthermore, activation of heat shock genes in Drosophila occurs with a corresponding increase in H3S10 phosphorylation only at heat shock loci (43).
Recent work in our laboratory has shown that within the Mediator complex, CDK8 can efficiently modify 315 H3 within histone octamers or chromatin templates (36) . Yet the activity of the free submodule may vary. Although the data in Figure 3 reveals the free CDK8 submodule can phosphorylate histone octamers, it does not address activity on chromatin. Therefore, we assembled core histone octamers into chromatin (Fig. 4A) and tested whether the free CDK8 submodule would similarly modify H3 in this context. As shown in Figure 4B , Although some studies have linked CDK8 to transcriptional activation (9, 14, 32) , the observation that 330 CDK8 can mediate H3S10 phosphorylation provides a molecular mechanism by which CDK8-dependent activation might occur. Although other transcriptionally-relevant kinases have been linked to H3S10 modification (e.g. PIM1, IKKα), these appear to regulate only a subset of genes (3, 59, 64). By contrast, CDK8 (as well as core Mediator) appears to be recruited to promoter and enhancer regions genome-wide (2, 63), suggesting that H3S10 phosphorylation by CDK8 may be a general phenomenon. In support of this, 335
shRNA knockdown of CDK8 causes a dramatic reduction in H3 containing the dual modification H3S10P/K14Ac, as reported previously (36) . This tandem H3 modification results from cooperative activity between CDK8 and GCN5L within Mediator. Upon probing H3S10P alone, we observed that CDK8 knockdown did not significantly reduce the levels of this singly-modified H3 in cells (data not shown). This result likely reflects high H3S10P levels from Aurora B kinase (a marker for mitosis) and also suggests 340 CDK8 primarily functions within Mediator (together with GCN5L) when phosphorylating H3 (36) .
Med12 activates the CDK8 kinase. Numerous biochemical roles for the CDK8/Cyclin C pair have been identified (albeit mostly in yeast). No clear function, however, has been determined for Med12 or Med13. Previous biochemical and genetic data in yeast indicated that ablation of either Med12 or Med13 is 345 phenotypically similar to mutations that inactivated CDK8 (7, 40) . However, subtle developmental differences have been noted upon comparing null mutants in Drosophila: although CDK8, Cyclin C, Med12, or Med13 mutant phenotypes are largely similar, Med12 or Med13 knockout cells did display differences in tarsal development when compared with cells null for CDK8 or Cyclin C (33) . Interestingly, when the 3-subunit partial CDK8 subcomplexes (CDK8/Cyclin C/Med12; CDK8/Cyclin C/Med13-see Fig. 1A ) were 350 tested for kinase function, only the 3-subunit complex containing Med12 was active, whereas the CDK8/Cyclin C/Med13 complex showed only weak activity toward the human CDK8 substrates tested (Fig.  5) . In fact, the 3-subunit CDK8/Cyclin C/Med12 complex possessed kinase activity comparable to the wildtype, 4-subunit complex for all substrates tested. Additionally, it is worth noting that the CDK8/Cyclin C dimer was inactive in these assays, unless titrated to 10-fold higher concentration relative to the 4-subunit 355 CDK8 subcomplex (Fig. 5, lanes 7 and 15) . We also used shRNA to knock down Med12 expression to further test the role of Med12 on CDK8 activity in human cells. However, this knockdown coordinately decreased CDK8 protein levels (data not shown) and therefore mimicked the CDK8 knockdown described below. 360
The data in Figure 5 reveals a previously unidentified biochemical function for human Med12 that distinguishes it from Med13. Future work will be necessary to identify the mechanism by which Med12 activates the CDK8 kinase. Notably, such a regulatory role for Med12 in yeast is not evident, as CDK8/Cyclin C retains its kinase function independent of Med12 and Med13 in vitro (40) . Whether Med12 is required for CDK8 activity in lower metazoans is not known; genetic experiments in worms and flies 365 indicate that Med12 or Med13 null mutations are indistinguishable during embryonic development (6, 23, 52, 55, 60). However, Fraser et al. recently completed a comprehensive RNAi screen in C. elegans which identified Med12 as one of only six "hub" genes that interact with a large number of genes from different signaling pathways (29) . Whether this distinction is related to Med12 regulation of CDK8 kinase activity remains to be determined, but this C. elegans screen does suggest that Med12 may perform biochemical 370 functions distinct from Med13 even in lower metazoans.
Isolation of an endogenous CDK8 subcomplex identifies potential regulatory cofactors.
The purification of a stable, active human CDK8 subcomplex from recombinant subunits suggested that a similar subcomplex may exist in human cells. Although previous work has clearly demonstrated that CDK8 can 375 reversibly associate with Mediator in human cells (37, 45) , it has not been established whether free, endogenous CDK8 subcomplexes serve any potential regulatory role independent of Mediator. Given the kinase targets of the recombinant CDK8 subcomplex identified here (which include TFIIH, the pol II CTD and histone H3), it was important to establish whether the free CDK8 submodule may exist as a stable, biochemically active entity in cells. Therefore, we sought to isolate free CDK8 subcomplexes directly from 380 human cells. Initial fractionation of HeLa nuclear extract over a phosphocellulose column enabled us to separate a potential CDK8 subcomplex from the majority of CDK8-Mediator: CDK8-Mediator was enriched in the P0.5M fraction whereas CDK8 subcomplex components were also present in the P0.3M fraction (Fig.  6A ). Further purification from the P0.3M fraction was completed by tracking kinase activity and protein subunits over additional ion-exchange, gel filtration, and affinity resins (Fig. 6B ). This purification scheme 385 resulted in isolation of a complex containing CDK8, Cyclin C, Med12, and Med13 that was free of core Mediator subunits, as shown by immunoblot assays (Fig. 7A ).
Most convincingly, MS analysis confirmed the presence of all four CDK8 subcomplex components in this sample (Fig. 7B) , whereas core Mediator subunits were not represented (although see Fig. 7B ). Notably, 390 CDK8-like (CDK8L; also called CDC2L6 or CDK11), a paralog of CDK8, was observed to co-purify with the endogenous CDK8 subcomplex. Immunoblots of the purified endogenous subcomplex showed no evidence of the CDK8 antibody cross-reacting with CDK8L. For this reason, and the fact that the CDK8 antibody used in the final affinity purification step is directed against a region of CDK8 (aa 424-464) not conserved within CDK8L, we conclude CDK8L most likely associates together with CDK8 in a single 395 subcomplex. Confirmation of this will ultimately require reagents specific for CDK8L.
MS analysis also identified other submodule-associated factors, including DNA-PK, GCN1L1, and the TRiC chaperonin complex (Fig. 7B) . The presence of DNA-PK and TRiC was further substantiated with immunoblotting experiments ( Fig. 7C ; antibodies against CDK8L and GCN1L1 are not available). 400
Additionally, CDK8 subcomplex components were observed to co-IP with DNA-PK and the TRiC subunit TCP-1β (Fig. 7D) . Given the rigorous purification protocol, including a final CDK8 antibody binding/elution step followed by separation based upon size (glycerol gradient step), it is likely that TRiC, DNA-PK and GCN1L1 are in fact associated with the CDK8 submodule and do not co-purify as individual entities. However, we cannot rule out the possibility that TRiC, DNA-PK, or GCN1L1 may bind the CDK8 405 submodule in a mutually exclusive fashion. Collectively, the data in Figure 7 demonstrate that the free CDK8 subcomplex can exist as a stable entity in human cells. Factors associated with the endogenous CDK8 subcomplex, however, distinguish it from the recombinant, four-subunit CDK8 subcomplex and suggest a means to regulate its activity and stability within cells. Given the critical role of CDK8 in gene regulation and oncogenesis (1, 12, 38) , it is likely that multiple mechanisms have evolved to control its 410 biological function.
The biological relevance of DNA-PK, GCN1L1, and TRiC association with the CDK8 submodule awaits elucidation in future studies. DNA-PK is well-established in DNA repair mechanisms and is peripherally implicated in transcriptional regulation (49); much less is known about GCN1L1, although its yeast ortholog 415 has been shown to bind and regulate the GCN2 kinase (15, 26) . The co-purification of the chaperonin TRiC with the endogenous CDK8 submodule is particularly intriguing. TRiC does not appear to be a general chaperonin. Instead, it displays specificity for a subset of regulatory complexes, including elongin BC and SMRT-HDAC3 (11, 16) . The results shown here identify the CDK8 submodule as another potential TRiCregulated complex. Notably, TRiC is critical for the formation of an active human Cyclin E/CDK2 complex 420 (58) and therefore its association with the CDK8 submodule may reflect similar roles in the formation of a stable, active subcomplex. Also noteworthy is the ability of TRiC to modulate aggregation of poly-Q tracts in the Huntington protein (4, 51) . Med12 contains a Q-rich region at its C-terminus and TRiC may help regulate interactions from this domain. 425
That TRiC might regulate CDK8 submodule interactions is further supported by electron microscopy (EM) analysis of the endogenous CDK8 submodule. Alignment and 2D classification of single-particle images revealed the presence of complexes of size and shape consistent with the free CDK8 submodule, as expected (data not shown). In addition, 2D averages of single-particle images clearly showed TRiC complexes whose large, central cavity was occupied with protein density (Fig. 7E) . Mammalian TRiC has a distinct barrel 430 shape consisting of stacked eight-membered rings with an outer diameter of approximately 150 Å and a length of 160 Å. TRiC utilizes ATP hydrolysis to aid in folding cargo proteins located within its 80 Å-diameter interior cavity. EM analysis and 3D reconstruction of the recombinant CDK8 subcomplex (M.K., K.M, and D.T., unpublished results) indicates its overall dimensions are slightly larger than the TRiC cavity could accommodate. Yet conformational shifts within the CDK8 subcomplex may facilitate its sequestration 435 within the TRiC central cavity, and/or the CDK8 submodule may exist as a partially-assembled entity within TRiC. However, since both CDK8 and Med13 were found to co-IP with an antibody against TRiC (Fig. 7D) , this suggests the entire CDK8 subcomplex might associate with the TRiC chaperonin. Although additional experiments will be necessary to delineate the means by which TRiC might regulate the CDK8 submodule, the EM data suggests that TRiC may sequester the submodule as a simple means of regulating its interactions 440 with other proteins such as core Mediator or its kinase substrates.
The endogenous CDK8 subcomplex displays altered substrate specificity. Following purification of the endogenous CDK8 subcomplex, we tested its kinase activity against known human substrates. Notably, the endogenous subcomplex displayed similar-but not identical-kinase activity relative to the recombinant 445 subcomplex. The endogenous sample resembled the recombinant CDK8 subcomplex in its phosphorylation of histone H3, Med13, and CDK8 ( Fig. 8A and data not shown). Although these results may reflect the activity of associated factors-particularly CDK8L-the similarity relative to the recombinant subcomplex implicates CDK8 in these modifications. We cannot, however, rule out phosphorylation by CDK8L in these experiments. CDK8L is a paralog of CDK8 and may possess similar substrate specificity. By contrast, 450 DNA-PK is unlikely to contribute to the kinase activity observed in Figure 8A because DNA-PK requires association with DNA to become an active kinase (49) and the endogenous subcomplex is not active in assays containing DNA (i.e. chromatin substrates-see Fig. 8A ). Moreover, addition of the DNA-PK inhibitor wortmannin had no effect on kinase activity of the endogenous CDK8 subcomplex under the conditions tested here (Fig. 8B) . 455 Strikingly, the endogenous subcomplex was unable to phosphorylate the pol II CTD. When normalizing for kinase activity toward histone H3, the endogenous CDK8 subcomplex phosphorylated the CTD with 2% efficiency compared to the recombinant subcomplex (Fig. 8C) . Given this clear difference in substrate specificity relative to the recombinant subcomplex-and relative to CDK8-Mediator, which can also 460 phosphorylate the pol II CTD-we sought to further test this result in human cells. Therefore, we examined whether knockdown of CDK8 would impact cellular levels of phosphorylated pol II CTD and observed that CDK8 knockdown did not appreciably impact global CTD phosphorylation patterns (S2 or S5; data not shown). These results are consistent with studies of yeast CDK8 (srb10), in which CDK8 kinase inhibition did not notably impact global pol II CTD phosphorylation (32) . Because human (and yeast) cells contain 465 multiple kinases capable of pol II CTD phosphorylation, the minimal impact of human CDK8 knockdown on global CTD phosphorylation was not unexpected. It remains possible that CDK8-dependent phosphorylation of the pol II CTD might regulate a subset of human genes.
Concluding remarks. Given the functionally diverse targets for the CDK8 kinase, including histone H3, 470 TFIIH, Med13, pol II CTD, precise temporal or context-dependent regulation of CDK8 substrate specificity may be a critical factor controlling gene expression in humans. We have identified several means by which CDK8 kinase activity might be regulated in cells. First, the kinase activity of the CDK8 submodule is dependent upon Med12. Second, incorporation into Mediator regulates CDK8 substrate specificity toward H3S10 within chromatin. Third, MS analysis of the endogenous CDK8 subcomplex identified CDK8L, the 475 TRiC chaperonin, GCN1L1, and DNA-PK as potential modifiers of CDK8 activity within the free subcomplex, and evidence that TRiC might help regulate CDK8 submodule interactions was obtained by EM analysis of endogenous subcomplexes. It is also plausible that phosphorylation or other post-translational modifications within the subcomplex itself may impact its kinase activity. Since the CDK8 subcomplex appears to regulate transcription genome-wide (e.g. via regulation of Mediator), a variety of mechanisms 480 may exist to control CDK8 function.
That the CDK8 subcomplex is stable and biochemically active apart from Mediator in cells suggests the subcomplex may function autonomously to regulate gene expression. Yet how might the free subcomplex be targeted to its substrates? Notably, Med12 and CDK8 are known to interact directly with a number of DNA-485 binding transcription factors, which would provide a means for targeting the free CDK8 subcomplex to specific genomic locations (14, 17, 24, 47, 56, 62) . Alternately, the CDK8 subcomplex may contain chromatin-targeting domains (e.g. cryptic bromodomains or chromodomains) that remain unidentified. Recruitment may also be mediated through one of the subcomplex-associated factors, such as DNA-PK or the TRiC chaperonin, identified in the MS analysis. It is important to note, however, that the Mediator 490 complex is more generally targeted by DNA-binding transcription factors; consequently, association with Mediator may enable more widespread targeting of the CDK8 subcomplex to appropriate regulatory sites. Although the majority of CDK8 subcomplexes appear to be Mediator-associated in cells, we estimate that a significant fraction (up to 30%) of CDK8 submodule components may exist independent of Mediator in HeLa cells (see Materials and Methods and Fig. 9 ). 495
It is notable that histone H3, Med13, and CDK8 itself are not modified by the CDK8 subcomplex in yeast, nor is the yeast CDK8 subcomplex dependent upon Med12 for activity (18, 40) . This is perhaps to be expected given the extensive sequence divergence within Mediator subunits over evolutionary time. Indeed, compared with the rest of the general transcription machinery (e.g. TFIID, TFIIH, pol II), Mediator has 500 diverged most significantly (30) . This substantial sequence divergence may be reflected in the distinct activity and substrate specificity of the human CDK8 subcomplex.
ACKNOWLEDGMENTS
We thank Bob Roeder for providing the Med12 cDNA, Emma Lees for providing cDNAs for CDK8 and 505
Cyclin C, and Karolin Luger for cDNAs encoding core histones. The 5S G5E4 template was a gift from Jerry Workman. This work was supported by the NCI P01 CA112181 (DJT) and R01 CA117907 (JME) and in part by NIH grants T32 GM07135 and T32 GM065103 (MTK and KDM). endogenous CDK8 subcomplex (eK8). The identity of each band is indicated and was determined by mass spectrometry. The number of unique peptide matches is shown in parenthesis. Peptide matches shown each had a Mascot Mowse score greater than 30. Note that 2 core Mediator subunits were detected in the analysis (Med14 and Med24); * The CDK8L band contained 6 total non-redundant peptide identifications, with 4 peptides unique to CDK8L within the human IPI database and 2 peptides that overlap with the CDK8 565 sequence. † The CDK8 band contained 2 non-redundant peptide matches, with one unique to CDK8 and one that is shared withCDK8L. 
